Vijaya Diagnostic Centre financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹231cr+22.8% on Q1 FY26
Net profit
₹53.1cr+37.6% on Q1 FY26
EBITDA margin
42.7%+3.6 pts on Q1 FY26
EPS
₹5.16+37.2% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue231188+22.8%
EBITDA98.573.5+34.0%
EBITDA margin42.7%39.1%+3.6 pts
Profit before tax70.952.2+35.9%
Net profit53.138.6+37.6%
EPS₹5.16₹3.76+37.2%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹231 crNet profit₹53.1 crNet margin23.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
14,846————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
268268197131163
0.00.03.42.71.9
14,578————
857814681548459
—+19.5%+24.4%+19.3%—
362337273221182
42.2%41.4%40.1%40.3%39.6%
266245203164120
18717314412085.2
21.9%21.2%21.1%21.8%18.6%
₹18.22₹16.81₹13.90₹11.55₹8.22
—+20.9%+20.4%+40.4%—
—271224183165
—−183−95.6−88.0−125
87.987.912995.339.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIJAYA₹1,442.80

Vijaya Diagnostic Centre Ltd.

· Pharma & Health
₹ CrorePeersTHYROCAREMETROPOLISLALPATHLABRAINBOWPOLYMEDPFIZERONESOURCEKIMSMcap ₹14,846 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————14,846.0
- Cash, Equiv & ST Investments163.2131.4197.4268.1268.1
+ Minority Interest1.92.73.40.00.0
Enterprise Value————14,577.9
Revenue459.2547.8681.4814.2857.1
Growth %, YoY—+19.3+24.4+19.5—
EBITDA182.0220.9273.2336.9361.9
Margin %39.6440.3240.1041.3842.23
EBIT120.3163.9202.6245.1265.9
Net Income85.2119.6143.8173.0187.5
Margin %18.5521.8421.1021.2421.87
EPS, Adj (current shares)8.2211.5513.9016.8118.22
Growth %, YoY—+40.4+20.4+20.9—
Cash from Operations164.6183.3224.5270.6—
Capital Expenditures-124.8-88.0-95.6-182.7—
Free Cash Flow39.895.3128.987.987.9
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Vijaya Diagnostic Centre financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Vijaya Diagnostic Centre (NSE: VIJAYA) had a market capitalisation of ₹15,066 crore at the 29 October 2026 close (₹1,464.20 a share), a PE ratio of 80.4 on the last four quarters' profit and a price-to-book ratio of 15.74. In FY26 its consolidated net profit was ₹173 crore on revenue of ₹814 crore; in Q1 FY27 (April–June 2026) it was ₹53.1 crore, up 38.5% year on year. It had no borrowings on 31 March 2026. Promoters held 52.46% of the shares on 30 September 2026.

Share price used
₹1,464.20 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Vijaya Diagnostic Centre at a glance · consolidated

Market cap
₹15,066 Crat ₹1,464.20 · 29 Oct close
PE ratio (last 4 quarters)
80.487.1 on FY26 profit
Price to book (PB)
15.74book value ₹93.02 a share
ROE (FY26)
19.7%unchanged vs FY25ROCE 19.7%
Debt to equity
0.00net cash ₹281 Cr
Promoter holding
52.46%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.14%₹2 a share in 12 months
Net worth
₹957 Cr+20.3% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹87.9 Cr−31.8% vs FY25

Questions

What is the Vijaya Diagnostic Centre PE ratio today?

Vijaya Diagnostic Centre's PE ratio is 80.4 at the 29 October 2026 close (₹1,464.20 a share): a market capitalisation of ₹15,066 crore divided by consolidated net profit of ₹187 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹173 crore) it is 87.1.

What is the Vijaya Diagnostic Centre PB ratio (price to book value)?

Vijaya Diagnostic Centre's price-to-book (PB) ratio is 15.74 at the 29 October 2026 close: a market capitalisation of ₹15,066 crore divided by shareholders' equity (book value) of ₹957 crore on 31 March 2026. That is a book value of ₹93.02 per share against a share price of ₹1,464.20.

What is the Vijaya Diagnostic Centre net worth?

Vijaya Diagnostic Centre's net worth — shareholders' equity in its consolidated balance sheet — was ₹957 crore on 31 March 2026, up 20.3% from ₹796 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹15,066 crore at the 29 October 2026 close.

What is the Vijaya Diagnostic Centre market cap?

Vijaya Diagnostic Centre's market capitalisation was ₹15,066 crore at the 29 October 2026 close: 10.29 crore shares at ₹1,464.20 each.

Is Vijaya Diagnostic Centre debt free?

Yes. Vijaya Diagnostic Centre had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹281 crore of cash, bank balances and current investments.

What is the Vijaya Diagnostic Centre EPS?

Vijaya Diagnostic Centre's basic earnings per share (EPS) were ₹16.81 in FY26, against ₹13.95 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹18.23.

What is the Vijaya Diagnostic Centre debt to equity ratio?

Vijaya Diagnostic Centre's debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹957 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Vijaya Diagnostic Centre book value per share?

Vijaya Diagnostic Centre's book value per share was ₹93.02 on 31 March 2026: shareholders' equity of ₹957 crore divided by the 10.29 crore shares in issue, up 20.0% from ₹77.53 a year earlier. The share price at the 29 October 2026 close was ₹1,464.20.

What is the Vijaya Diagnostic Centre dividend yield?

Vijaya Diagnostic Centre's dividend yield is 0.14% at the 29 October 2026 close: dividends of ₹2 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,464.20. They were ₹2 on 16 September 2026.

What is the Vijaya Diagnostic Centre ROE and ROCE?

In FY26, Vijaya Diagnostic Centre's return on equity (ROE) was 19.7% and its return on capital employed (ROCE) was 19.7%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 19.7% and ROCE 20.1%.

What is the Vijaya Diagnostic Centre promoter holding?

Promoters held 52.46% of Vijaya Diagnostic Centre on 30 September 2026, down 0.05 percentage points from 52.51% the previous quarter and down 0.14 percentage points from 52.60% a year earlier, according to the shareholding pattern filed with NSE.

What is the Vijaya Diagnostic Centre shareholding pattern?

On 30 September 2026, Vijaya Diagnostic Centre's shares were held by promoters 52.46%, foreign portfolio investors (FII/FPI) 10.66%, domestic institutions (DII) 32.50% (including mutual funds at 31.44%) and retail and other non-institutional investors 4.38%. Over the year, FII holding was down 7.61 percentage points from 18.27% and DII holding was up 7.16 percentage points from 25.34%.

What is the Vijaya Diagnostic Centre dividend in 2026 and its record date?

In 2026, Vijaya Diagnostic Centre has declared one dividend: ₹2 with record date 16 September 2026.

What is the Vijaya Diagnostic Centre free cash flow?

In FY26, Vijaya Diagnostic Centre generated ₹271 crore of cash from operations and spent ₹183 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹87.9 crore. In FY25 it was ₹129 crore.

When are the Vijaya Diagnostic Centre next results?

Vijaya Diagnostic Centre will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

What are the Vijaya Diagnostic Centre latest quarterly results?

Vijaya Diagnostic Centre's latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net profit ₹53.1 crore, up 38.5% from ₹38.3 crore in Q1 FY26; revenue from operations ₹231 crore, up 22.8% year on year.

What is the Vijaya Diagnostic Centre revenue and profit in FY26?

In FY26 (April 2025–March 2026), Vijaya Diagnostic Centre's consolidated net profit was ₹173 crore, up 20.9% from ₹143 crore in FY25, on revenue from operations of ₹814 crore (up 19.5%). Over three years, from FY23, net profit was up 104.4%.

How does the Vijaya Diagnostic Centre PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Vijaya Diagnostic Centre's PE ratio is 87.1, the highest of the four: Thyrocare Technologies 50.3, Metropolis Healthcare 60.4 and Dr. Lal Path Labs 63.5, a peer average of 58.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Vijaya Diagnostic Centre compare with its peers?

On FY26 consolidated figures, against Thyrocare Technologies, Metropolis Healthcare and Dr. Lal Path Labs: Vijaya Diagnostic Centre's operating margin of 30.1% is the highest of the four (Thyrocare Technologies 24.5%, Metropolis Healthcare 16.2%, Dr. Lal Path Labs 22.5%; peer average 21.1%); its return on equity of 19.7% is the third highest of the four (Thyrocare Technologies 28.8%, Metropolis Healthcare 13.4%, Dr. Lal Path Labs 21.6%; peer average 21.2%); its revenue growth over three years of 21.0% a year is the highest of the four (Thyrocare Technologies 16.3% a year, Metropolis Healthcare 12.8% a year, Dr. Lal Path Labs 11.1% a year; peer average 13.4% a year).

Vijaya Diagnostic Centre vs Thyrocare Technologies: how do they compare?

In FY26, Vijaya Diagnostic Centre earned net profit of ₹173 crore on revenue of ₹814 crore, against ₹163 crore on ₹829 crore for Thyrocare Technologies. Vijaya Diagnostic Centre's operating margin was 30.1% (Thyrocare Technologies 24.5%) and its return on equity 19.7% (Thyrocare Technologies 28.8%). At the 29 October 2026 close, Vijaya Diagnostic Centre's market capitalisation was ₹15,066 crore against ₹8,205 crore for Thyrocare Technologies, and its PE ratio on FY26 profit 87.1 against 50.3.

Where do these Vijaya Diagnostic Centre figures come from?

From Vijaya Diagnostic Centre's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.